Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicola Mathieson

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Leukemia Research|April 22, 2019
Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocolsPere Gascón, Andriy Krendyukov, Nicola Mathieson, et al.
Future Oncology (London, England)|May 23, 2019
Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancerBernardo Rapoport, Ramin B Arani, Nicola Mathieson, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 24, 2019
Extrapolation in Practice: Lessons from 10 Years with Biosimilar FilgrastimPere Gascon, Andriy Krendyukov, Nicola Mathieson, et al.
NPJ Primary Care Respiratory Medicine|March 9, 2017
The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β<sub>2</sub>-agonists in the United Kingdom: a cross-sectional analysisIan D Pavord, Nicola Mathieson, Anna Scowcroft, et al.
NPJ Primary Care Respiratory Medicine|December 7, 2017
Author Correction: The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β<sub>2</sub>-agonists in the United Kingdom: a cross-sectional analysisIan D Pavord, Nicola Mathieson, Anna Scowcroft, et al.
Journal of Medical Economics|August 22, 2019
Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphomaAli McBride, Andriy Krendyukov, Nicola Mathieson, et al.
Current Medical Research and Opinion|April 8, 2022
A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006)Sanjiv S Agarwala, Ulrich Nagl, Xinghua Guo, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 12, 2023
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiativeBernardo Leon Rapoport, Marcial Garcia-Morillo, Carme Font, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Leukemia Research|April 22, 2019
Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocolsPere Gascón, Andriy Krendyukov, Nicola Mathieson, et al.
Future Oncology (London, England)|May 23, 2019
Meta-analysis comparing incidence of grade 3-4 neutropenia with ALK inhibitors and chemotherapy in patients with non-small-cell lung cancerBernardo Rapoport, Ramin B Arani, Nicola Mathieson, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|August 24, 2019
Extrapolation in Practice: Lessons from 10 Years with Biosimilar FilgrastimPere Gascon, Andriy Krendyukov, Nicola Mathieson, et al.
NPJ Primary Care Respiratory Medicine|March 9, 2017
The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β<sub>2</sub>-agonists in the United Kingdom: a cross-sectional analysisIan D Pavord, Nicola Mathieson, Anna Scowcroft, et al.
NPJ Primary Care Respiratory Medicine|December 7, 2017
Author Correction: The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β<sub>2</sub>-agonists in the United Kingdom: a cross-sectional analysisIan D Pavord, Nicola Mathieson, Anna Scowcroft, et al.
Journal of Medical Economics|August 22, 2019
Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphomaAli McBride, Andriy Krendyukov, Nicola Mathieson, et al.
Current Medical Research and Opinion|April 8, 2022
A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006)Sanjiv S Agarwala, Ulrich Nagl, Xinghua Guo, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 12, 2023
A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiativeBernardo Leon Rapoport, Marcial Garcia-Morillo, Carme Font, et al.
Pageof 1